Literature DB >> 6195469

Effect of verapamil on left ventricular function at rest and during exercise in normal men.

H J D'Agostino, E L Pritchett, D G Shand, R H Jones.   

Abstract

Verapamil is a calcium channel blocking agent used primarily for treatment of arrhythmias and coronary artery disease. It may also depress myocardial contractility. The purpose of this study was to assess the effect of verapamil on left ventricular function. Twelve normal men, 22-29 years of age, were studied at rest and during exercise, with and without verapamil, using first-pass radionuclide angiocardiography. Verapamil was administered by continuous intravenous infusion to produce steady-state blood levels of 106-123 ng/ml. The heart rate, ejection fraction, stroke volume index, and end-diastolic volume index were measured with and without the drug. Verapamil increased the mean resting heart rate from 74 to 78 beats/min (p = 0.001), decreased the mean stroke volume index from 48 to 42 ml/m2 (p = 0.01), and decreased the mean end-diastolic volume index from 77 to 71 ml/m2 (p less than 0.05). No changes in cardiac index, ejection fraction, end-systolic volume index, or peak systolic pressure/end-systolic volume ratio were observed at rest. No differences occurred in exercise hemodynamics. Thus verapamil at therapeutic dose levels did not significantly depress contractility or have other clinically important hemodynamic effects at rest or during exercise in normal subjects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195469     DOI: 10.1097/00005344-198309000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  1 in total

1.  A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals.

Authors:  Erika Mae Summers; Nicholas Ray Blickenstaff; Garrett Curtis Coman; Thomas Bernd Martins; Harry Raymond Hill; Richard Dennis Sontheimer
Journal:  Ann Transl Med       Date:  2017-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.